Why the study?
Brugada syndrome can cause lethal ventricular arrhythmias, and the authors sought to showcase thoracoscopic bilateral cardiac sympathetic denervation as a treatment option for refractory cases.
Does thoracoscopic bilateral cardiac sympathetic denervation ameliorate refractory ventricular arrhythmias in a patient with Brugada syndrome on ECMO?
Does thoracoscopic bilateral cardiac sympathetic denervation ameliorate refractory ventricular arrhythmias in a patient with Brugada syndrome on ECMO?
Thoracoscopic bilateral cardiac sympathetic denervation can be an effective treatment for refractory ventricular arrhythmias in patients with Brugada syndrome requiring ECMO.
May support CSD for refractory Brugada VT; hypothesis-generating, needs prospective validation.
Genetic syndrome such as Brugada syndrome can lead to lethal ventricular arrhythmias. Cardiac sympathetic denervation has been shown to be effective in ameliorating refractory ventricular arrhythmias. We present a 33-year-old black female with a medical history of Brugada syndrome with an implantable cardiac defibrillator who presented with refractory ventricular tachycardia leading to cardiogenic shock, requiring extracorporeal membrane oxygenation. The patient subsequently underwent bilateral stellate ganglion sympathetic denervation in the setting of refractory ventricular arrhythmias. We present this case report to showcase that thoracoscopic bilateral cardiac sympathetic denervation can be an effective treatment option for ventricular arrhythmias refractory to medical management.
No takes yet. Share an insight, caveat, or question.
Farran et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: